IL274797B2 - Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof - Google Patents

Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Info

Publication number
IL274797B2
IL274797B2 IL274797A IL27479720A IL274797B2 IL 274797 B2 IL274797 B2 IL 274797B2 IL 274797 A IL274797 A IL 274797A IL 27479720 A IL27479720 A IL 27479720A IL 274797 B2 IL274797 B2 IL 274797B2
Authority
IL
Israel
Prior art keywords
human
gene segments
mouse
genetically modified
gene
Prior art date
Application number
IL274797A
Other languages
English (en)
Hebrew (he)
Other versions
IL274797B1 (en
IL274797A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL274797A publication Critical patent/IL274797A/en
Publication of IL274797B1 publication Critical patent/IL274797B1/en
Publication of IL274797B2 publication Critical patent/IL274797B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL274797A 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof IL274797B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594946P 2017-12-05 2017-12-05
US201762594944P 2017-12-05 2017-12-05
US201762609241P 2017-12-21 2017-12-21
US201762609251P 2017-12-21 2017-12-21
PCT/US2018/063841 WO2019113065A1 (en) 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Publications (3)

Publication Number Publication Date
IL274797A IL274797A (en) 2020-07-30
IL274797B1 IL274797B1 (en) 2025-02-01
IL274797B2 true IL274797B2 (en) 2025-06-01

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
IL318197A IL318197A (en) 2017-12-05 2018-12-04 Non-human animals with engineered lambda immunoglobulin light chains and uses thereof
IL274797A IL274797B2 (en) 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL318197A IL318197A (en) 2017-12-05 2018-12-04 Non-human animals with engineered lambda immunoglobulin light chains and uses thereof

Country Status (24)

Country Link
US (3) US20210345591A1 (enExample)
EP (3) EP4596688A3 (enExample)
JP (2) JP7430636B2 (enExample)
KR (2) KR20250022220A (enExample)
CN (2) CN111432635B (enExample)
AU (2) AU2018381316B2 (enExample)
BR (1) BR112020011184A2 (enExample)
CA (1) CA3084049A1 (enExample)
DK (2) DK3720279T3 (enExample)
ES (2) ES3035461T3 (enExample)
FI (1) FI4140297T3 (enExample)
HR (2) HRP20221459T1 (enExample)
HU (2) HUE060608T2 (enExample)
IL (2) IL318197A (enExample)
LT (2) LT3720279T (enExample)
MX (2) MX2020005830A (enExample)
PL (2) PL4140297T3 (enExample)
PT (2) PT4140297T (enExample)
RS (2) RS67058B1 (enExample)
SG (1) SG11202003044SA (enExample)
SI (2) SI4140297T1 (enExample)
SM (2) SMT202200448T1 (enExample)
TW (2) TWI827567B (enExample)
WO (1) WO2019113065A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
CN114502725B (zh) * 2019-07-01 2025-09-12 特里安尼公司 转基因哺乳动物及使用方法
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
CN118511853A (zh) * 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2013096142A1 (en) * 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
US20130263293A1 (en) * 2012-03-28 2013-10-03 Kymab Limited Animal models and therapeutic molecules
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
US9346873B2 (en) * 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
AU8470301A (en) * 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
JP2011501652A (ja) * 2007-09-12 2011-01-13 プロビオドルグ エージー トランスジェニックマウス
ES2445193T3 (es) * 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) * 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US9346873B2 (en) * 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
WO2013096142A1 (en) * 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
WO2013116609A1 (en) * 2012-02-01 2013-08-08 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
US20130263293A1 (en) * 2012-03-28 2013-10-03 Kymab Limited Animal models and therapeutic molecules
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N ROUGEON ET AL,, CONSTITUTIVE EXPRESSION OF TERMINAL CONSTITUTIVE EXPRESSION OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE IN TRANSGENIC MICE IS SUFFICIENT FOR N REGION DIVERSITY TO OCCUR AT ANY LG LOCUS THROUGHOUT B CELL DIFFERENTIATION., 31 December 1997 (1997-12-31) *

Also Published As

Publication number Publication date
LT3720279T (lt) 2022-10-25
EP4140297A1 (en) 2023-03-01
HRP20221459T1 (hr) 2023-01-20
EP3720279B1 (en) 2022-09-21
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
CN111432635A (zh) 2020-07-17
KR102760506B1 (ko) 2025-02-04
FI4140297T3 (fi) 2025-07-10
EP4596688A2 (en) 2025-08-06
HUE071852T2 (hu) 2025-09-28
HUE060608T2 (hu) 2023-03-28
JP7765514B2 (ja) 2025-11-06
IL274797B1 (en) 2025-02-01
BR112020011184A2 (pt) 2020-11-17
KR20250022220A (ko) 2025-02-14
US20210292439A1 (en) 2021-09-23
TWI827567B (zh) 2024-01-01
RU2020118699A3 (enExample) 2022-04-07
JP7430636B2 (ja) 2024-02-13
AU2018381316B2 (en) 2025-06-26
PL3720279T3 (pl) 2023-01-16
MX2024004496A (es) 2024-05-08
MX2020005830A (es) 2020-08-20
SMT202500277T1 (it) 2025-09-12
JP2024036440A (ja) 2024-03-15
EP3720279A1 (en) 2020-10-14
US20210345591A1 (en) 2021-11-11
KR20200093570A (ko) 2020-08-05
US20190223418A1 (en) 2019-07-25
ES2928995T3 (es) 2022-11-24
DK4140297T3 (da) 2025-06-23
RU2020118699A (ru) 2022-01-10
EP4596688A3 (en) 2025-11-12
IL274797A (en) 2020-07-30
HRP20250920T1 (hr) 2025-09-26
AU2018381316A1 (en) 2020-04-23
ES3035461T3 (en) 2025-09-03
CN111432635B (zh) 2022-10-21
WO2019113065A1 (en) 2019-06-13
PT4140297T (pt) 2025-07-09
PL4140297T3 (pl) 2025-08-25
RS67058B1 (sr) 2025-08-29
DK3720279T3 (da) 2022-10-24
LT4140297T (lt) 2025-07-25
SMT202200448T1 (it) 2023-01-13
TW201938019A (zh) 2019-10-01
JP2021505141A (ja) 2021-02-18
RS63772B1 (sr) 2022-12-30
TW202438676A (zh) 2024-10-01
SI3720279T1 (sl) 2022-11-30
US11051498B2 (en) 2021-07-06
EP4140297B1 (en) 2025-05-21
IL318197A (en) 2025-03-01
CA3084049A1 (en) 2019-06-13
AU2025204547A1 (en) 2025-07-10
SI4140297T1 (sl) 2025-08-29
CN116058333A (zh) 2023-05-05
SG11202003044SA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
IL274797B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
HRP20191191T1 (hr) Miš sa zajedničkim lakim lancem
HRP20220253T1 (hr) Miševi s ograničenim teškim lancem imunoglobulina
NZ743520A (en) Humanized universal light chain mice
JP5756802B2 (ja) 最小ｃｄｒを有する抗体を産生するトランスジェニック動物
NZ730271A (en) Non-human animals expressing ph-sensitive immunoglobulin sequences
AU2024200582A1 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
CA2865644A1 (en) Mice that produce antigen-binding proteins with ph-dependent binding characteristics
IL305557A (en) Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
NZ763183B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
NZ763183A (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
US20210227811A1 (en) Transgenic chicken having an endogenous immunoglobulin heavy chain gene in which the igy ch1 coding sequence is functionally deleted
US12428471B2 (en) Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
US20250388651A1 (en) Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
US12102070B2 (en) Camelization of a human variable domain by gene conversion
AU2019284252B2 (en) Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
AU2025271118A1 (en) Transgenic chicken that makes antibodies with long CDR-H3s stabilized by multiple disulfide bridges and diversified by gene conversion
AU2019280049B2 (en) Non-human animals expressing ph-sensitive immunoglobulin sequences